Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Interleukin (IL)-1 impairs insulin secretion and induces β-cell apoptosis. Pancreatic β-cell IL-1 expression is increased and interleukin-1 receptor antagonist (IL-1Ra) expression reduced in patients with type 2 diabetes. Treatment with recombinant IL-1Ra improves glycemia and β-cell function and reduces inflammatory markers in patients with type 2 diabetes. Here we investigated the durability of these responses. RESEARCH DESIGN AND METHODS: Among 70 ambulatory patients who had type 2 diabetes, A1C >7.5%, and BMI >27 kg/m2 and were randomly assigned to receive 13 weeks of anakinra, a recombinant human IL-1Ra, or placebo, 67 completed treatment and were included in this double-blind 39-week follow-up study. Primary outcome was change in β-cell function after anakinra withdrawal. Analysis was done by intention to treat. RESULTS: Thirty-nine weeks after anakinra withdrawal, the proinsulin-to-insulin (PI/I) ratio but not stimulated C-peptide remained improved (by −0.07 [95% CI −0.14 to −0.02], P = 0.011) compared with values in placebo-treated patients. Interestingly, a subgroup characterized by genetically determined low baseline IL-1Ra serum levels maintained the improved stimulated C-peptide obtained by 13 weeks of IL-1Ra treatment. Reductions in C-reactive protein (−3.2 mg/l [−6.2 to −1.1], P = 0.014) and in IL-6 (−1.4 ng/l [−2.6 to −0.3], P = 0.036) were maintained until the end of study. CONCLUSIONS: IL-1 blockade with anakinra induces improvement of the PI/I ratio and markers of systemic inflammation lasting 39 weeks after treatment withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“lower levels of IL-1Ra may predict who maintains better β-cell function after an intervention to decrease islet inflammation70.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [70]
In the citing paper
“This treatment approach for type 2 diabetes is promising, as the improvement in levels of glucose and inflammatory markers was long-lasting110.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · cited 1×
“Secondary outcomes included change between baseline and 52 weeks in IL-6, C-reactive protein (CRP), insulin requirements, A1C, and the homeostasis model assessment– insulin sensitivity index (HOMA-Si) (18).”
Backgroundβ-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · cited 1×
“During the course of the disease beta-cell function progressively declines irrespective of treatment with glucose-lowering drugs (2-4).”
BackgroundU.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798 · cited 6×
“At baseline, and at 13 and 52 weeks, beta-cell secretory function was assessed by the fasting PI/I ratio and by a 2-hour oral glucose-tolerance test directly followed by a 12-minute intravenous glucose, glucagon and arginine stimulation test as described previously (16).”
BackgroundMethodResultInfluentialSelf-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationDiagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Increased Number of Islet-Associated Macrophages in Type 2 Diabetes
Ehses, J. A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J. A., Maor-Cahn, R., Gueripel, X., Ellingsgaard, H., Schneider, M. K. J., Biollaz, G., et al. (2007) · Diabetes · doi:10.2337/db06-1650 · Cited by 783 · cited 1×
“IL-1 production could thus originate from the betacell (7) or from macrophages infiltrating the islets (23) as the IL-1B gene is overexpressed in blood monocytes from patients with type 2 diabetes (24).”
BackgroundSelf-citation
Cited by
Items 301–400 of 407
Kuo, C. Y. J., Rupenthal, I. D., Booth, M., Murphy, R., & Mugisho, O. O. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3030039 · Cited by 5
Mandrup-Poulsen, T. R. (2012) · Nature · doi:10.1038/485s17a · Cited by 5
Self-citationMacronutrient intake, insulin secretion, oxidative stress & inflammation
Dandona, P., Ghanim, H., Chaudhuri, A., & Mohanty, P. (2016) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1807_16 · Cited by 5
Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
Schinner, S. (2010) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(10)79457-9 · Cited by 4
Quezada, N., Valencia, I., Torres, J., Maturana, G., Jaime Cerda, L., Arab, J. P., Fuentes, J. J., Pinto, C., Turiel, D., & Cortés, V. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001975 · Cited by 5
“17 Notably, pharmacological blocking of the IL-1 receptor with anakinra improves glycemic control in patients with type 2 diabetes (T2D), 18 19 suggesting a direct link between IL-1 β signaling and IR.”
Inflammatory Pathways Linked to Beta Cell Demise in Diabetes
Imai, Y., Morris, M. A., Dobrian, A. D., Taylor, D., & Nadler, J. L. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_30-2 · Cited by 6
“However, a subgroup who initially responded to anakinra by reduction in A1c after 13 weeks of treatment continued to maintain higher C-peptide compared with nonresponders after termination of anakinra (Larsen et al. 2009).”
BackgroundInflammation and Type 2 Diabetes
van Greevenbroek, M. M. J., Schalkwijk, C. G., & Stehouwer, C. D. A. (2017) · Wiley-VCH eBooks · doi:10.1002/9783527692156.ch47 · Cited by 6
Hanawa, H., Ota, Y., Ding, L., Chang, H., Yoshida, K., Otaki, K., Hao, K., Kasahara, S., Kodama, M., Nakazawa, M., et al. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9497-z · Cited by 4
Souza, J. D. P., Fischer, J. S., Jeanneau, K., Allard, C., Angevaare, E., Aschenbrenner, D., Bodendorf, U., Demarco, B., Gounarides, J., Killmer, S., et al. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.06.008 · Cited by 3
Self-citationNiu, B., Su, H., Xia, X., He, Q., Xue, Y., & Yan, X.-M. (2017) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2017.02.006 · Cited by 3
“Despite the evidence that the inflammatory cytokine IL-1b, interferon (IFN)-g, and tumor necrosis factor-a are involved in the development and progression of diabetes through damaging islet b cells, which is based on IL-1b single therapeutic monoclonal antibodies that protect islet b cells in Type 1 diabetes, the exac…”
BackgroundRemote ischemic conditioning: A potential therapeutic strategy of type 2 diabetes
Liu, J., Sun, X., Jin, H., Yan, X., Huang, S., Guo, Z., & Yang, Y. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110409 · Cited by 4
Diabetes diminishes muscle precursor cell-mediated microvascular angiogenesis
Acosta, F. M., Pacelli, S., & Rathbone, C. R. (2023) · PLoS ONE · doi:10.1371/journal.pone.0289477 · Cited by 3
“Among inflammatory molecules, IL-8 and GROα, have previously been identified as myokines responsible for reduced capillary formation in T2D [19, 43, 51].”
BackgroundInfluentialKötter, I., & Horneff, G. (2010) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-009-0530-7 · Cited by 3
Kostik, M. M. (2016) · Вопросы современной педиатрии · doi:10.15690/vsp.v15i6.1654 · Cited by 3
Faraj, M. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30042-2 · Cited by 6
Akujuru, E. E., Aprioku, J. S., & Okerengwo, A. (2020) · Comparative Clinical Pathology · doi:10.1007/s00580-019-03086-8 · Cited by 6
Ali, I. I., D’Souza, C. M., Nemmar, A., Ojha, S. K., & Adeghate, E. A. (2025) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70092 · Cited by 2
“41 Other than the medical drugs, the potential role of peptides such as adropin as anti-inflammatory agents against DM and other metabolic disorders has been investigated.”
The roles of NLRP3 inflammasome in diabetic cardiomyopathy and potential targeted therapeutics
Zhang, M., & Liu, Y. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102140 · Cited by 3
Autoimmune diseases and metabolic disorders: Molecular connections and potential therapeutic targets
Uddin, M. J., Tran, D. K., Hannan, M. A., Hasan-Al-Faruque, Rahman, M. A., Moni, A., Lam, N. T., Ngọc, V. T. N., & Chu, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85415-3.00018-0 · Cited by 2
Klashami, Z. N., Mostafavi, A., Roudbordeh, M. G., Abbasi, A., Ebrahimi, P., Asadi, M., & Amoli, M. M. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08759-w · Cited by 2
“Cytokines cause changes in gene expression by activating signaling pathways after binding to specific receptors on the surface of target cells [35].”
Earpina, S., McDonough, K., Yeboah-Awudzi, M., Cook, K. J., Aggarwal, S., & Losso, J. N. (2020) · Food Production Processing and Nutrition · doi:10.1186/s43014-020-00023-z · Cited by 3
Treatment of Inflammasome-Related Disorders
Lachmann, H. J. (2011) · Springer eBooks · doi:10.1007/978-3-0348-0148-5_14 · Cited by 2
“Conditions range from the very rare such as the inherited autoinflammatory disorders particularly cryopyrin-associated periodic syndrome (CAPS) to much common acquired disorders such as gout [1], silica-mediated pulmonary fibrosis [2], as well as perhaps myeloma [3], atherosclerosis [4], and type II diabetes mellitus…”
BackgroundTXNIP is a Mediator of ER Stress-Induced β-Cell Inflammation and Apoptosis: A Dissertation
Oslowski, C. M. (2012) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/mj81-rb58 · Cited by 2
Modulating Inflammatory Cytokines
Gresnigt, M. S., & van de Veerdonk, F. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803302-9.00008-7 · Cited by 4
Caspases: Regulatory Mechanisms and Their Implications in Pathogenesis and Therapeutics
Parui, A. L., & Bose, K. (2017) · Springer eBooks · doi:10.1007/978-981-10-6141-7_18 · Cited by 2
Könemann, S., Dörr, M., & Felix, S. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803267-1.00028-4 · Cited by 5
Meur, G., Anindya, R., & Rutter, G. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13195-0.00010-7 · Cited by 3
Interactions between nutrition, obesity and the immune system
Strandberg, L. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 4
Nanotherapeutics in metabolic diseases–Associated infections
Jaiswal, V., Bisht, S., Prakash, S., Raina, D., & Singh, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28836-4.00026-3 · Cited by 1
Obesity-Associated Chronic Inflammation: A Protective Mechanism against Type 2 Diabetes
Ye, J. (2025) · Immune discovery. · doi:10.70322/immune.2025.10007 · Cited by 1
Yoda, M., Nomura, N., Yoda, S., Kagotani, M., Murakami, A., Namai, F., Fujii, T., Tochio, T., Sato, T., & Shimosato, T. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/6006491 · Cited by 2
Acierno, C., Cavallo, M., D’Ardes, D., Boccatonda, A., Nilo, D., & Caturano, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188063 · Cited by 1
“…the anakinra trial bears on the last of these: the improvement in the proinsulin-to-insulin ratio and in inflammatory markers persisted after withdrawal, whereas the gain in stimulated C-peptide did not, except in a subgroup characterised by genetically determined low baseline IL-1Ra levels [74].”
Current literature in diabetes
(2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1017 · Cited by 1
Serum Proteome Pool Changes in Type 2 Diabetic Patients Treated with Anakinra
Koefoed, M. M., Larsen, C. M., Faulenbach, M. V., Vaag, A. A., Ehses, J. A., Donath, M. Y., McGuire, J. N., Pociot, F., & Mandrup-Poulsen, T. R. (2010) · Clinical Proteomics · doi:10.1007/s12014-010-9056-x · Cited by 1
“However, although anakinra markedly reduced serum CRP and IL-6, these inflammatory markers were not correlated to clinical outcome [2, 7].”
BackgroundSelf-citationThe Immune System and Inflammation in Type 2 Diabetes
Macedo, R. G. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_11 · Cited by 4
An Overview of Hypoglycemic Biological Drugs
Chen, H., & Wang, Q. (2021) · Springer eBooks · doi:10.1007/978-981-15-8791-7_3 · Cited by 2
The Effects and Treatment of Inflammation on Diabetes Mellitus and Cardiovascular Disease
Hattar, L., Mumtaz, T., Mouhayyar, C. E., Matevossian, A., & Johnstone, M. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_10 · Cited by 1
Physical Activity and Inflammation
Loretelli, C., D’Addio, F., Nasr, M. B., & Fiorina, P. (2023) · Springer eBooks · doi:10.1007/978-3-031-27192-2_9 · Cited by 1
Orhanoğlu, T. (2024) · İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi · doi:10.38079/igusabder.1207998 · Cited by 1
Firms chase diabetic inflammation with anti-IL-1β antibodies
Sheridan, C. (2010) · Nature Biotechnology · doi:10.1038/nbt0610-533 · Cited by 1
Anti-Obesity and Anti-Hypertensive Action of Calanus Oil
Salma, W. (2015) · NORA - Norwegian Open Research Archives · Cited by 2
Ruscitti, P., Sesti, G., Cipriani, P., Gerli, R., & Giacomelli, R. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220047 · Cited by 1
Garlanda, C., Ceglie, I. D., & Jaillon, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00178-2 · Cited by 1
Regulation of Dual Leucine Zipper Kinase (DLK) by Prediabetic Signals
Babaeikelishomi, R. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4117
Neuroimmune Signaling in the Hippocampus: Mechanisms of Risk and Resilience
Williamson, L. L. (2014) · DukeSpace (Duke University)
Depression and Diabetes Prevention
Hermanns, N. (2013) · Wiley eBooks · doi:10.1002/9781118661321.ch5
Broncopneumopatia cronica ostruttiva e comorbidità croniche
Nozzoli, G. E. C., Gensini, G., & Fabbri, L. M. (2013) · Italian Journal of Medicine · doi:10.4081/itjm.2011.1.s1
Type 2 Diabetes and Islet Inflammation
Donath, M. Y. (2013) · Else Kröner-Fresenius Symposia · doi:10.1159/000346508
Self-citationWu, C., Lee, W.-J., & Chen, C.-Y. (2014) · Obesity Surgery · doi:10.1007/s11695-014-1399-3
BPCO, obesità, sindrome metabolica e diabete
Gulli, G., & Miselli, V. (2011) · Italian Journal of Medicine · doi:10.1016/j.itjm.2011.01.011 · Cited by 1
“[15] Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY,”
BackgroundOVERCOMING SELF-REACTIVITY THROUGH IMMUNOLOGICAL AND METABOLIC REDOX MODULATION
Delmastro-Greenwood, M. M. (2012) · D-Scholarship@Pitt (University of Pittsburgh)
The Beta Cell in Metabolic Syndrome
Zarrouki, B., Fontès, G., Semache, M., Amyot, J., & Poitout, V. (2013) · Springer eBooks · doi:10.1007/978-3-319-01008-3_5
Analysis of Cytokines in Sera from Type 1 Diabetic Patients at Diagnosis
Yoon, I. S., Shin, C. H., & Yang, S. W. (2011) · Journal of Korean Society of Pediatric Endocrinology · doi:10.6065/jkspe.2011.16.1.13
Genetic variations in the NALP3 inflammasome
Verma, D. (2009)
Inflammation and Adipose Dysfunction
Shah, R. D., & Reilly, M. P. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1607-5_9
“Larsen et al. [ 65 ] found that type 2 diabetic patients treated with recombinant IL-1RA for 13 weeks had sustained improvement in glycemia and reduced circulating inflammatory markers compared to placebo.”
BackgroundVu, B. G., Schlievert, P. M., Squier, C. A., Yahr, T. L., Horswill, A. R., & Apicella, M. A. (2014) · doi:10.17077/etd.y6n7p4ee
Recent Developments in Diabetes Therapy
Sen, S., Chakraborty, R., & De, B. (2016) · Springer eBooks · doi:10.1007/978-981-10-1542-7_12
Palmitic Acid Activation of Dendritic Cells: Implications for Type 2 Diabetes
Nicholas, D. (2015) · The Scholars Repository - LLU (Loma Linda University)
A bioluminescence sensor of NLRP3 inflammasome activation
Winek, M. A. (2016) · Loyola eCommons (Loyola University of Chicago)
Börchers, S. (2014) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4556
The role of IL-1Ra in periodontal tissue destruction and its potential for therapeutic drugs
Ishihara, Y. (2017) · 日本歯周病学会会誌 · doi:10.2329/perio.59.101
Influence of biologics on carbohydrate metabolism and risk of diabetes
Kondratyeva, L. V., Попкова, Т. В., & Nasonov, E. L. (2019) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2019-222-228
Kalemci, S., Zeybek, A., Mıçılı, S. Ç., Sarıhan, A., Çalışır, M., Şimşek, A., Akın, F., İhtiyar, A., & Yılmaz, O. (2019) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0013.7878
Kulkarni, A. (2020) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1921
Wolmarans, D. W., Steyn, S. F., & Brand, L. (2020) · South African General Practitioner · doi:10.36303/sagp.2020.3.0024
Actions of Novel Hybrid Peptides on Hyperglycaemia and Immunomodulation in Experimental Diabetes
Ofosu, W. A. (2020) · UEL Research Repository (University of East London) · doi:10.15123/uel.8887z
(2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833c4b2b
Inflammatory Pathways Linked to β Cell Demise in Diabetes
Imai, Y., Morris, M. A., Dobrian, A. D., Taylor, D., & Nadler, J. L. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_30
Anderstam, B., Lindholm, B., & Stenvinkel, P. (2012) · Wiley eBooks · doi:10.1002/9781118424032.ch17
Faculty Opinions recommendation of IL-1 blockade in autoinflammatory syndromes.
Lopez-Escamez, J. A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718239727.793549284
Chen, S., Fu, Z., Yu, C., Liu, C., Li, M., Wu, G., Guo, X. H., Liu, X., Wang, L., & Wang, J. (2023) · Analytical Science Advances · doi:10.1002/ansa.202200019
Salah, N. (2022) · theses.fr (ABES) · doi:10.70675/e80bdb23z5944z4c12z9d5azbe48cce7108d · Cited by 1
Negash, M., Girma, T., Chanyalew, M., Alemayehu, D. H., Alcantara, D., Davey, G., Boyton, R. J., Altmann, D. M., Newport, M. J., & Howe, R. (2024) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed9110252
“IL-1 β is also a prominent pro-inflammatory cytokine whose aberrant expression and regulation drives disease progres-Trop sion in different chronic inflammatory conditions, such as type 2 diabetes [21], and chronic inflammation involving skin and bone [22].”
Najafi, A., Momeni‐Moghaddam, M. A., Salarbashi, D., Beidokhti, N. A., Rahmani, M., & Khorasani, M. (2024) · مجله دانشگاه علوم پزشکی اراک · doi:10.61186/jams.27.3.131
Wong, M., Mastronardi, C. A., Paz-Filho, G., Simeonovic, C. J., & Licinio, J. (2025) · Genomic psychiatry : · doi:10.61373/gp025l.0056
Complex Roles of Macrophages in Lipid Metabolism and Metabolic Disease: A Dissertation
Negrin, K. A. (2014) · eScholarship@UMassChan · doi:10.13028/m24p4s · Cited by 1
Ishihara, Y., Kamei, H., Kamiya, Y., Izawa, A., Mizutani, H., Suzuki, M., Noguchi, T., & Mitani, A. (2014) · 日本歯周病学会会誌 · doi:10.2329/perio.56.272
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26650548
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26650527
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26650542
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26650524
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26650539
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2023) · Figshare · doi:10.6084/m9.figshare.24761282
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26650533
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26650551
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26650530
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2024) · Figshare · doi:10.6084/m9.figshare.24761980
Lyngbæk, M. P. P., Legaard, G. E., Bennetsen, S. L., Feineis, C. S., Rasmussen, V., Moegelberg, N., Brinkløv, C. F., Nielsen, A. B., Kofoed, K. S., Lauridsen, C. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361947
Lyngbæk, M. P. P., Legaard, G. E., Bennetsen, S. L., Feineis, C. S., Rasmussen, V., Moegelberg, N., Brinkløv, C. F., Nielsen, A. B., Kofoed, K. S., Lauridsen, C. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361935
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26650536
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26650545
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26650521
Jangsiripornpakorn, J., Srisuk, S., Chailurkit, L., Nimitphong, H., Saetung, S., & Ongphiphadhanakul, B. (2022) · Figshare · doi:10.6084/m9.figshare.19311344
Lyngbæk, M. P. P., Legaard, G. E., Bennetsen, S. L., Feineis, C. S., Rasmussen, V., Moegelberg, N., Brinkløv, C. F., Nielsen, A. B., Kofoed, K. S., Lauridsen, C. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361932
Lyngbæk, M. P. P., Legaard, G. E., Bennetsen, S. L., Feineis, C. S., Rasmussen, V., Moegelberg, N., Brinkløv, C. F., Nielsen, A. B., Kofoed, K. S., Lauridsen, C. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361944
Lyngbæk, M. P. P., Legaard, G. E., Bennetsen, S. L., Feineis, C. S., Rasmussen, V., Moegelberg, N., Brinkløv, C. F., Nielsen, A. B., Kofoed, K. S., Lauridsen, C. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361929
Lyngbæk, M. P. P., Legaard, G. E., Bennetsen, S. L., Feineis, C. S., Rasmussen, V., Moegelberg, N., Brinkløv, C. F., Nielsen, A. B., Kofoed, K. S., Lauridsen, C. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361941
Diabetes tipo II e resolvinas D1
da Silva, I. A. M. B. (2015) · Repositório Comum (Repositório Científico de Acesso Aberto de Portugal)
Sabiha, N., Kaur, A., & Mohd, S. (2026) · Plant Science Today · doi:10.14719/pst.12116
Jeyananthan, P., Chandrasiri, H. V. B. L., & Ashfa, A. G. F. (2026) · Experimental Eye Research · doi:10.1016/j.exer.2026.110988
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T.
- Affiliations
- Hagedorn Research Institute and Steno Diabetes Center, Gentofte, Denmark;
- University Hospital Zurich (CH)
- Lund University (SE)
- University of Copenhagen (DK)
- Corresponding author
- Mandrup-Poulsen, Thomas
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-06-19
- Volume
- 32
- Issue
- 9
- Pages
- 1663-1668
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2732140
- OpenAlex
- W2137334382
- Cited by
- 401
- References
- 28
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 27 · 2023: 15 · 2022: 14 · 2021: 28 · 2020: 16 · 2019: 21 · 2018: 11 · 2017: 23 · 2016: 21 · 2015: 27 · 2014: 36 · 2013: 42 · 2012: 32
- FWCI
- 35.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- interleukin-1 receptor antagonist, anakinra, type 2 diabetes, beta-cell function, insulin secretion, beta-cell apoptosis, IL-1 blockade, C-peptide, proinsulin/insulin ratio, C-reactive protein, interleukin-6, systemic inflammation, treatment withdrawal, glycemic control
- MeSH terms
- Diabetes Mellitus, Type 2, Female, Humans, Male, Antirheumatic Agents, Insulin-Secreting Cells, Interleukin 1 Receptor Antagonist Protein, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.